MEK blockade converts AML differentiating response to retinoids into extensive apoptosis

Michele Milella, Marina Konopleva, Cristina M. Precupanu, Yoko Tabe, Maria Rosaria Ricciardi, Chiara Gregorj, Steven J. Collins, Bing Z. Carter, Carmen D'Angelo, Maria Teresa Petrucci, Robin Foà, Francesco Cognetti, Agostino Tafuri, Michael Andreeff

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

The aberrant function of transcription factors and/or kinase-based signaling pathways that regulate the ability of hematopoietic cells to proliferate, differentiate, and escape apoptosis accounts for the leukemic transformation of myeloid progenitors. Here, we demonstrate that simultaneous retinoid receptor ligation and blockade of the MEK/ERK signaling module, using the small-molecule inhibitor CI-1040, result in a strikingly synergistic induction of apoptosis in both acute myeloid leukemia (AML) and acute promyelocytic leukemia (APL) cells with constitutive ERK activation. This proapoptotic synergism requires functional RAR and RXR retinoid receptors, as demonstrated using RAR- and RXR-selective ligands and RAR-defective cells. In the presence of MEK inhibitors, however, retinoid-induced chromatin remodeling, target-gene transcription, and granulocytic differentiation are strikingly inhibited and apoptosis induction becomes independent of death-inducing ligand/receptor pairs; this suggests that apoptosis induction by combined retinoids and MEK inhibitors is entirely distinct from the classical "postmaturation" apoptosis induced by retinoids alone. Finally, we identify disruption of Bcl-2-dependent mitochondrial homeostasis as a possible point of convergence for the proapoptotic synergism observed with retinoids and MEK inhibitors. Taken together, these results indicate that combined retinoid treatment and MEK blockade exert powerful antileukemic effects and could be developed into a novel therapeutic strategy for both AML and APL.

Original languageEnglish
Pages (from-to)2121-2129
Number of pages9
JournalBlood
Volume109
Issue number5
DOIs
Publication statusPublished - Mar 1 2007

Fingerprint

Mitogen-Activated Protein Kinase Kinases
Retinoids
Acute Myeloid Leukemia
Apoptosis
Acute Promyelocytic Leukemia
Ligands
Chromatin Assembly and Disassembly
Transcription
Chromatin
Ligation
Homeostasis
Transcription Factors
Phosphotransferases
Genes
Chemical activation
Molecules

ASJC Scopus subject areas

  • Hematology

Cite this

Milella, M., Konopleva, M., Precupanu, C. M., Tabe, Y., Ricciardi, M. R., Gregorj, C., ... Andreeff, M. (2007). MEK blockade converts AML differentiating response to retinoids into extensive apoptosis. Blood, 109(5), 2121-2129. https://doi.org/10.1182/blood-2006-05-024679

MEK blockade converts AML differentiating response to retinoids into extensive apoptosis. / Milella, Michele; Konopleva, Marina; Precupanu, Cristina M.; Tabe, Yoko; Ricciardi, Maria Rosaria; Gregorj, Chiara; Collins, Steven J.; Carter, Bing Z.; D'Angelo, Carmen; Petrucci, Maria Teresa; Foà, Robin; Cognetti, Francesco; Tafuri, Agostino; Andreeff, Michael.

In: Blood, Vol. 109, No. 5, 01.03.2007, p. 2121-2129.

Research output: Contribution to journalArticle

Milella, M, Konopleva, M, Precupanu, CM, Tabe, Y, Ricciardi, MR, Gregorj, C, Collins, SJ, Carter, BZ, D'Angelo, C, Petrucci, MT, Foà, R, Cognetti, F, Tafuri, A & Andreeff, M 2007, 'MEK blockade converts AML differentiating response to retinoids into extensive apoptosis', Blood, vol. 109, no. 5, pp. 2121-2129. https://doi.org/10.1182/blood-2006-05-024679
Milella M, Konopleva M, Precupanu CM, Tabe Y, Ricciardi MR, Gregorj C et al. MEK blockade converts AML differentiating response to retinoids into extensive apoptosis. Blood. 2007 Mar 1;109(5):2121-2129. https://doi.org/10.1182/blood-2006-05-024679
Milella, Michele ; Konopleva, Marina ; Precupanu, Cristina M. ; Tabe, Yoko ; Ricciardi, Maria Rosaria ; Gregorj, Chiara ; Collins, Steven J. ; Carter, Bing Z. ; D'Angelo, Carmen ; Petrucci, Maria Teresa ; Foà, Robin ; Cognetti, Francesco ; Tafuri, Agostino ; Andreeff, Michael. / MEK blockade converts AML differentiating response to retinoids into extensive apoptosis. In: Blood. 2007 ; Vol. 109, No. 5. pp. 2121-2129.
@article{de54ce9f0f414068aee7ebdd4994d375,
title = "MEK blockade converts AML differentiating response to retinoids into extensive apoptosis",
abstract = "The aberrant function of transcription factors and/or kinase-based signaling pathways that regulate the ability of hematopoietic cells to proliferate, differentiate, and escape apoptosis accounts for the leukemic transformation of myeloid progenitors. Here, we demonstrate that simultaneous retinoid receptor ligation and blockade of the MEK/ERK signaling module, using the small-molecule inhibitor CI-1040, result in a strikingly synergistic induction of apoptosis in both acute myeloid leukemia (AML) and acute promyelocytic leukemia (APL) cells with constitutive ERK activation. This proapoptotic synergism requires functional RAR and RXR retinoid receptors, as demonstrated using RAR- and RXR-selective ligands and RAR-defective cells. In the presence of MEK inhibitors, however, retinoid-induced chromatin remodeling, target-gene transcription, and granulocytic differentiation are strikingly inhibited and apoptosis induction becomes independent of death-inducing ligand/receptor pairs; this suggests that apoptosis induction by combined retinoids and MEK inhibitors is entirely distinct from the classical {"}postmaturation{"} apoptosis induced by retinoids alone. Finally, we identify disruption of Bcl-2-dependent mitochondrial homeostasis as a possible point of convergence for the proapoptotic synergism observed with retinoids and MEK inhibitors. Taken together, these results indicate that combined retinoid treatment and MEK blockade exert powerful antileukemic effects and could be developed into a novel therapeutic strategy for both AML and APL.",
author = "Michele Milella and Marina Konopleva and Precupanu, {Cristina M.} and Yoko Tabe and Ricciardi, {Maria Rosaria} and Chiara Gregorj and Collins, {Steven J.} and Carter, {Bing Z.} and Carmen D'Angelo and Petrucci, {Maria Teresa} and Robin Fo{\`a} and Francesco Cognetti and Agostino Tafuri and Michael Andreeff",
year = "2007",
month = "3",
day = "1",
doi = "10.1182/blood-2006-05-024679",
language = "English",
volume = "109",
pages = "2121--2129",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "5",

}

TY - JOUR

T1 - MEK blockade converts AML differentiating response to retinoids into extensive apoptosis

AU - Milella, Michele

AU - Konopleva, Marina

AU - Precupanu, Cristina M.

AU - Tabe, Yoko

AU - Ricciardi, Maria Rosaria

AU - Gregorj, Chiara

AU - Collins, Steven J.

AU - Carter, Bing Z.

AU - D'Angelo, Carmen

AU - Petrucci, Maria Teresa

AU - Foà, Robin

AU - Cognetti, Francesco

AU - Tafuri, Agostino

AU - Andreeff, Michael

PY - 2007/3/1

Y1 - 2007/3/1

N2 - The aberrant function of transcription factors and/or kinase-based signaling pathways that regulate the ability of hematopoietic cells to proliferate, differentiate, and escape apoptosis accounts for the leukemic transformation of myeloid progenitors. Here, we demonstrate that simultaneous retinoid receptor ligation and blockade of the MEK/ERK signaling module, using the small-molecule inhibitor CI-1040, result in a strikingly synergistic induction of apoptosis in both acute myeloid leukemia (AML) and acute promyelocytic leukemia (APL) cells with constitutive ERK activation. This proapoptotic synergism requires functional RAR and RXR retinoid receptors, as demonstrated using RAR- and RXR-selective ligands and RAR-defective cells. In the presence of MEK inhibitors, however, retinoid-induced chromatin remodeling, target-gene transcription, and granulocytic differentiation are strikingly inhibited and apoptosis induction becomes independent of death-inducing ligand/receptor pairs; this suggests that apoptosis induction by combined retinoids and MEK inhibitors is entirely distinct from the classical "postmaturation" apoptosis induced by retinoids alone. Finally, we identify disruption of Bcl-2-dependent mitochondrial homeostasis as a possible point of convergence for the proapoptotic synergism observed with retinoids and MEK inhibitors. Taken together, these results indicate that combined retinoid treatment and MEK blockade exert powerful antileukemic effects and could be developed into a novel therapeutic strategy for both AML and APL.

AB - The aberrant function of transcription factors and/or kinase-based signaling pathways that regulate the ability of hematopoietic cells to proliferate, differentiate, and escape apoptosis accounts for the leukemic transformation of myeloid progenitors. Here, we demonstrate that simultaneous retinoid receptor ligation and blockade of the MEK/ERK signaling module, using the small-molecule inhibitor CI-1040, result in a strikingly synergistic induction of apoptosis in both acute myeloid leukemia (AML) and acute promyelocytic leukemia (APL) cells with constitutive ERK activation. This proapoptotic synergism requires functional RAR and RXR retinoid receptors, as demonstrated using RAR- and RXR-selective ligands and RAR-defective cells. In the presence of MEK inhibitors, however, retinoid-induced chromatin remodeling, target-gene transcription, and granulocytic differentiation are strikingly inhibited and apoptosis induction becomes independent of death-inducing ligand/receptor pairs; this suggests that apoptosis induction by combined retinoids and MEK inhibitors is entirely distinct from the classical "postmaturation" apoptosis induced by retinoids alone. Finally, we identify disruption of Bcl-2-dependent mitochondrial homeostasis as a possible point of convergence for the proapoptotic synergism observed with retinoids and MEK inhibitors. Taken together, these results indicate that combined retinoid treatment and MEK blockade exert powerful antileukemic effects and could be developed into a novel therapeutic strategy for both AML and APL.

UR - http://www.scopus.com/inward/record.url?scp=33847373890&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847373890&partnerID=8YFLogxK

U2 - 10.1182/blood-2006-05-024679

DO - 10.1182/blood-2006-05-024679

M3 - Article

C2 - 17077328

AN - SCOPUS:33847373890

VL - 109

SP - 2121

EP - 2129

JO - Blood

JF - Blood

SN - 0006-4971

IS - 5

ER -